What does Dulaglutide do? Benefits and evidence

A weekly GLP-1 medicine approved for type 2 diabetes and lower heart-event risk.

Also called: Trulicity, LY2189265.

GLP-1 / GIP / glucagon agonists · GLP-1 receptor agonist · Evidence: Approved drug.

Dulaglutide is a weekly GLP-1 medicine for type 2 diabetes. It is a GLP-1 and antibody-fragment fusion protein. Trials support blood-sugar control and fewer major heart events in adults with diabetes. It is not approved for weight management. Stomach upset is common, and dehydration, pancreatitis and eye complications need attention.

  • Trulicity is approved for type 2 diabetes from age 10, and to lower major heart-event risk in some adults with diabetes. (Drug label)
  • In a trial, the 1.5 mg dose lowered the long-term blood sugar score by 1.51 points, versus 0.46 on placebo. (Studied in a trial)
  • In a large heart trial, 12.0% of people on dulaglutide had a major heart event, versus 13.4% in the comparison group. (Studied in a trial)
  • Weight also fell in diabetes trials, though it is not approved for weight loss. (Studied in a trial)

Uses in the sources

  • Approved for type 2 diabetes and lower major heart-event risk in adults with diabetes and established disease or multiple risk factors. (Drug label) (source)
  • Weight fell in diabetes trials. Trulicity has no US weight-management indication. (Studied in a trial) (source)

Related to Dulaglutide

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.